Benefits
Body fat and weight reduction
In a 16-week placebo-controlled trial in 151 obese premenopausal women, a fucoxanthin plus pomegranate seed oil product (2.4 mg fucoxanthin daily) was followed by about 5 kg weight loss and 3.5 kg less body fat. A 12 mg fucoxanthin trial in 28 adults reported lower weight from baseline, while 4.4 mg added to diet and exercise gave no extra loss. ThinOgen itself has no indexed trial.
White fat thermogenesis (UCP1) in animal studies
In mice fed fucoxanthin, white fat weight fell and UCP1, a heat-producing protein normally found in brown fat, was clearly expressed in white fat. This proposed 'browning' effect has been shown in animals, not in people, and should not be assumed to explain any weight change in humans.
Triglycerides, insulin and metabolic markers
Serum triglycerides fell in the combination trial. In a 12-week trial in 28 adults with metabolic syndrome, 12 mg of fucoxanthin a day was followed by lower weight, waist, blood pressure and triglycerides and higher insulin secretion compared with baseline, and no improvement in insulin sensitivity was reported. Both trials were small or used a combination product.
Liver fat reduction
In the same 16-week trial of fucoxanthin plus pomegranate seed oil, liver fat fell, and liver enzymes fell in women who started with high liver fat. This is one study of a two-ingredient product, not ThinOgen, and it does not show that a supplement treats or prevents liver disease.
Mechanism of action
UCP1 expression in white fat (mice)
UCP1 lets mitochondria release energy as heat instead of storing it. In fucoxanthin-fed mice, UCP1 protein and mRNA appeared in white fat, where it is normally scarce, and white fat weight fell. This has not been shown in people.
Fat-cell formation in cell culture
In 3T3-L1 cells, a mouse cell line used to study fat-cell formation, fucoxanthin and its metabolite fucoxanthinol reduced fat build-up as the cells matured and lowered PPAR-gamma, a master regulator of fat-cell genes. This is cell-culture work and has not been shown in people.
Brown seaweed source
BGG extracts ThinOgen mainly from kombu (Laminaria japonica) and also offers a wakame (Undaria pinnatifida) version. Fucoxanthin is a major carotenoid of edible brown seaweeds such as wakame and hijiki.
Clinical trials
16-week double-blind, randomized, placebo-controlled trial of Xanthigen (300 mg pomegranate seed oil plus 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) daily, with lower-dose and fucoxanthin-alone arms for energy expenditure. (Abidov et al. 2010, Diabetes Obes Metab)
151 obese non-diabetic premenopausal women: 113 with liver fat above 11 percent and 38 with normal liver fat.
On the 2.4 mg product, body weight fell 5.5 kg in women with high liver fat and 4.9 kg in those with normal liver fat, with body fat down about 3.5 kg and lower liver fat, triglycerides and C-reactive protein. The abstract gives no placebo-arm weight figure. The product combined fucoxanthin with pomegranate seed oil, so the result cannot be assigned to fucoxanthin alone, and ThinOgen was not tested.
Randomized, double-blind, placebo-controlled trial of 12 mg fucoxanthin or placebo once daily for 12 weeks, with an oral glucose tolerance test before and after. (López-Ramos et al. 2023, J Med Food)
28 adults diagnosed with metabolic syndrome in Mexico.
In the fucoxanthin group, body weight, BMI, waist, blood pressure and triglycerides were lower after 12 weeks than at baseline and insulin secretion rose; no improvement in insulin sensitivity was reported. The abstract reports before-and-after changes, the trial was small, and ThinOgen was not the product tested.
Randomized, double-blind, placebo-controlled trial of a Phaeodactylum tricornutum microalgae extract providing 4.4 mg/day fucoxanthin for 12 weeks, added to supervised exercise and a reduced-calorie diet. (Dickerson et al. 2024, Nutrients)
37 overweight but otherwise healthy women (average age about 29).
Fucoxanthin did not produce additional weight or fat loss beyond diet and exercise. The authors reported secondary improvements in bone density, step count, resting heart rate, aerobic capacity and blood lipids. Two authors were affiliated with the sponsor.